Company Filing History:
4 out of 16 
1 out of 97 
Years Active: 2016-2021
Title: Fabrice Heitz: Innovator in Diabetes Research
Introduction
Fabrice Heitz is a notable inventor based in Bartenheim, France. He has made significant contributions to the field of diabetes research, particularly through his innovative work on human islet amyloid polypeptide (hIAPP). With a total of 4 patents to his name, Heitz is recognized for his advancements in immunotherapy and diagnostics related to diabetes.
Latest Patents
Heitz's latest patents include the development of specific antibodies targeting human islet amyloid polypeptide (hIAPP). These antibodies, along with their fragments, derivatives, and variants, are designed for use in pharmaceutical and diagnostic compositions aimed at IAPP and proIAPP targeted immunotherapy. Additionally, he has described compounds that can antagonize IAPP-induced beta-cell damage and impaired glucose tolerance, which are critical symptoms associated with type 2 diabetes mellitus.
Career Highlights
Throughout his career, Fabrice Heitz has worked with prominent organizations such as Neurimmune Holding AG and the University of Zurich. His work has focused on creating innovative solutions to combat diabetes and improve patient outcomes.
Collaborations
Heitz has collaborated with notable colleagues in his field, including Jan Grimm and Feng Chen. Their combined expertise has contributed to the advancement of research in diabetes and related therapies.
Conclusion
Fabrice Heitz stands out as an influential inventor in the realm of diabetes research. His innovative patents and collaborations reflect his commitment to improving healthcare solutions for individuals affected by diabetes.